Not logged in.png)
Share.png)
SaveReceptor tyrosine kinases inhibit bone morphogenetic protein-smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells
Nakayama, K; Tamura, Y; Suzawa, M; Harada, S; Fukumoto, S; Kato, M; Miyazono, K; Rodan, GA; Takeuchi, Y; Fujita, T Share Save Identification of Anabolic Selective Androgen Receptor Modulators with Reduced Activities in Reproductive Tissues and Sebaceous GlandsSchmidt, Azriel; Harada, Shun-Ichi; Kimmel, Donald B.; Bai, Chang; Chen, Fang; Rutledge, Su Jane; Vogel, Robert L.; Scafonas, Angela; Gentile, Michael A.; Nantermet, Pascale V.; McElwee-Witmer, Sheila; Pennypacker, Brenda; Masarachia, Patricia; Sahoo, Soumya P.; Kim, Yuntae; Meissner, Robert S.; Hartman, George D.; Duggan, Mark E.; Rodan, Gideon A.; Towler, Dwight A.; Ray, William J. Share Save Control of rat tail skin temperature regulation by estrogen receptor-beta selective ligandOpas, Evan E.; Scafonas, Angela; Nantermet, Pascale V.; Wilkening, Robert R.; Birzin, Elizabeth T.; Wilkinson, Hilary; Colwell, Lawrence F.; Schaeffer, James M.; Towler, Dwight A.; Rodan, Gideon A.; Schmidt, Azriel Share Save Bone density, strength, and formation in adult cathepsin K (-/-) micePennypacker, B.; Shea, M.; Liu, Q.; Masarachia, P.; Saftig, R.; Rodan, S.; Rodan, G.; Kimmel, D. Share Save Share Save Share Save Share Save Share Save Share Save Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin KPalmer, JT; Bryant, C; Wang, DX; Davis, DE; Setti, EL; Rydzewski, RM; Venkatraman, S; Tian, ZQ; Burrill, LC; Mendonca, RV; Springman, E; McCarter, J; Chung, T; Cheung, H; Janc, JW; McGrath, M; Somoza, JR; Enriquez, P; Yu, ZW; Strickley, RM; Liu, L; Venuti, MC; Percival, MD; Falgueyret, JP; Prasit, P; Oballa, R; Riendeau, D; Young, RN; Wesolowski, G; Rodan, SB; Johnson, C; Kimmel, DB; Rodan, G Share Save Share Save Nonpeptide αvβ3 antagonists.: Part 11:: Discovery and preclinical evaluation of potent αvβ3 antagonists for the prevention and treatment of osteoporosisColeman, PJ; Brashear, KM; Askew, BC; Hutchinson, JH; McVean, CA; Duong, LT; Feuston, BP; Fernandez-Metzler, C; Gentile, MA; Hartman, GD; Kimmel, DB; Leu, CT; Lipfert, L; Merkle, K; Pennypacker, B; Prueksaritanont, T; Rodan, GA; Wesolowski, GA; Rodan, SB; Duggan, ME Share Save Share Save Share Save Nonpeptide αvβ3 antagonists.: 8.: In vitro and in vivo evaluation of a potent αvβ3 antagonist for the prevention and treatment of osteoporosisHutchinson, JH; Hatczenko, W; Brashear, KM; Breslin, MJ; Coleman, PJ; Duong, LT; Fernandez-Metzler, C; Gentile, MA; Fisher, JE; Hartman, GD; Huff, JR; Kimmel, DB; Leu, CT; Meissner, RS; Merkle, K; Nagy, R; Pennypacker, B; Perkins, JJ; Prueksaritanont, T; Rodan, GA; Varga, SL; Wesolowski, GA; Zartman, AE; Rodan, SB; Duggan, ME Share Save Share Save IL-1 regulates cytoskeletal organization in osteoclasts via TNF receptor-associated factor 6/c-Src complexNakamura, I; Kadono, Y; Takayanagi, H; Jimi, E; Miyazaki, T; Oda, H; Nakamura, K; Tanaka, S; Rodan, GA; Duong, LT Share Save Share Save Prostaglandin receptor EP4 mediates the bone anabolic effects of PGE2Machwate, M; Harada, S; Leu, CT; Seedor, G; Labelle, M; Gallant, M; Hutchins, S; Lachance, N; Sawyer, N; Slipetz, D; Metters, KM; Rodan, SB; Young, R; Rodan, GA Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}